The company's portfolio includes small molecule kinase inhibitors that target critical signaling pathways in cancer cells, with its first commercial product, COPIKTRA, indicated for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and relapsed or refractory follicular lymphoma. Verastem Oncology's pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of various cancers with limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. The company is committed to pursuing unexplored pathways and delivering novel therapies to address high unmet needs in RAS pathway-driven cancers.